A novel approach for prevention and dissolution of cholesterol gallstones

Liver International

Volumn 28, Issue 7, 2008, Pages 906-907

  Floreani, Annarosa ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; BILE SALT; CELL SURFACE PROTEIN; CHOLECYSTOKININ; CHOLESTEROL; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER X RECEPTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NIEMANN PICK C1 LIKE 1 PROTEIN; OCTAPEPTIDE; PHOSPHOLIPID; URSODEOXYCHOLIC ACID;

BILE FLOW; BILIARY EXCRETION; CARDIOVASCULAR DISEASE; CHOLESTEROL STONE; CHOLESTEROL SYNTHESIS; EDITORIAL; GRAVIMETRY; HUMAN; HYPERCHOLESTEROLEMIA; INTESTINE ABSORPTION; LIPID ABSORPTION; MICROSCOPY; NONHUMAN; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION;

ANIMALS; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL; DISEASE MODELS, ANIMAL; GALLSTONES; HUMANS;

EID: 47949094132     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01812.x     Document Type: Editorial

References (16)

1. Portincasa P, Moschetta A, Palasciano G. Cholesterol gallstone disease. Lancet 2006; 368: 230-9.
2. Admirand WH, Small DM. The physicochemical basis of cholesterol gallstone formation in man. J Clin Invest 1968; 47: 1043-52.
3. Wang DQ, Carey MC. Characterization of crystallization pathways during cholesterol precipitation from human gallbladder biles: Identical pathways to corresponding model biles with three predominating sequences. J Lipid Res 1996; 37: 2539-49.
4. Paumgartner G, Pauletzki J, Sackmann M. Ursodeoxycholic acid treatment of gallstone disease. Scand J Gastroenterol 1994; 204 (Suppl.): 27-31.
5. Kullak-Ublick GA, Stieger B, Meier PJ. Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology 2004; 126: 322-42.
6. Makishima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids. Science 1999; 284: 1362-5.
7. Rader DJ. Liver X receptor and farnesoid X receptor as therapeutic targets. Am J Cardiol 2007; 100: N15-9.
8. Uppal H, Zhai Y, Gangopadhhyay A, et al. Activation of liver X receptor sensitizes mice to gallbladder cholesterol crystallization. Hepatology 2008; 47: 1331-42.
9. Wang DQ, Paigen B, Carey MC. Phenotypic characterization of Lith genes that determine susceptibility to cholesterol cholelitiasis in inbred mice: Physical-chemistry of gallbladder bile. J Lipid Res 1997; 38: 1395-411.
10. Lammert F, Wang DQ. New insights into the genetic regulation of intestinal cholesterol absorption. Gastroenterology 2005; 129: 718-34.
11. Temel RE, Tang W, Ma Y, et al. Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J Clin Invest 2007; 117: 1968-78.
12. Zuniga S, Molina H, Azocar L, et al. Ezetimibe prevents cholesterol gallstone formation in mice. Liver Int 2008; 28: 935-47.
13. Mathur A, Walker JJ, Al-Azzawi HH, et al. Ezetimibe ameliorates cholecystosteatosis. Surgery 2007; 142: 228-33.
14. Wang HH, Portincasa P, Mendez-Sanchez H, Uribe M, Wang DQ. Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones. Gastroenterology 2008; 47: 2112-26.
15. Feldman T, Koren M, Insull W Jr, et al. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am J Cardiol 2004; 93: 1481-6.
16. Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol 2004; 93: 1487-94.